RT Journal Article
SR Electronic
T1 Domiciliary high-flow nasal cannula oxygen therapy for stable hypercapnic COPD patients: a prospective, multicenter, open-label, randomized controlled trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.21.21257508
DO 10.1101/2021.05.21.21257508
A1 Nagata, Kazuma
A1 Horie, Takeo
A1 Chohnabayashi, Naohiko
A1 Jinta, Torahiko
A1 Tsugitomi, Ryosuke
A1 Shiraki, Akira
A1 Tokioka, Fumiaki
A1 Kadowaki, Toru
A1 Watanabe, Akira
A1 Fukui, Motonari
A1 Kitajima, Takamasa
A1 Sato, Susumu
A1 Tsuda, Toru
A1 Kishimoto, Nobuhito
A1 Kita, Hideo
A1 Mori, Yoshihiro
A1 Nakayama, Masayuki
A1 Tsuboi, Tomomasa
A1 Yoshida, Makoto
A1 Hataji, Osamu
A1 Fuke, Satoshi
A1 Kagajo, Michiko
A1 Nishine, Hiroki
A1 Kobayashi, Hiroyasu
A1 Nakamura, Hiroyuki
A1 Okuda, Miyuki
A1 Tachibana, Sayaka
A1 Takata, Shohei
A1 Osoreda, Hisayuki
A1 Minami, Kenichi
A1 Nishimura, Takashi
A1 Ishida, Tadashi
A1 Terada, Jiro
A1 Takeuchi, Naoko
A1 Kohashi, Yasuo
A1 Inoue, Hiromasa
A1 Nakagawa, Yoko
A1 Kikuchi, Takashi
A1 Tomii, Keisuke
A1 FLOCOP study investigators
YR 2021
UL http://medrxiv.org/content/early/2021/05/23/2021.05.21.21257508.abstract
AB Background The effectiveness of the domiciliary use of high-flow nasal cannula oxygen therapy (HFNC) in patients with chronic hypercapnic respiratory failure due to chronic obstructive pulmonary disease (COPD) remains controversial.Objectives To investigate the efficacy and safety of domiciliary HFNC use in stable hypercapnic COPD patients.Methods This multicenter, open-label, randomized controlled trial enrolled patients with stable hypercapnic COPD. Over 52 weeks, we compared long-term oxygen therapy (LTOT) alone versus domiciliary HFNC plus LTOT (HFNC/LTOT). The primary endpoint was the frequency of moderate/severe COPD exacerbations. We also compared changes from baseline levels in arterial blood gas, SpO2, pulmonary function, health-related quality of life (HRQOL), and a six-minute walk test.Results We enrolled 104 patients in total; from these, we removed mismatching patients and then assigned 49 and 50 patients to HFNC/LTOT and LTOT groups, respectively, for safety analysis; 47 and 46 patients for HFNC/LTOT and LTOT groups, respectively, for efficacy analysis. Thirty-seven (79%) and 41 patients (89%) in HFNC/LTOT and LTOT, respectively, completed the final evaluation. HFNC significantly reduced the frequency of COPD exacerbations and prolonged the duration without moderate or severe COPD exacerbations over the 52-week study period (p = 0.002, p = 0.032, respectively). The adjusted odds ratios (95% confidence intervals [CIs]) of the frequency of COPD exacerbations in LTOT against HFNC/LTOT was 2.85 (1.48, 5.47). The median survival time (95% CI) to the first COPD exacerbation with moderate or severe for the LTOT group was 25 weeks (14.1, 47.4); however, the HFNC/LTOT group did not reach the median survival time. HFNC also caused statistically significant differences (p < 0.05) in the SpO2, FVC (%FVC), and FEV1 (%FEV1); however, these improvements were transient. There were no other improvements in arterial blood gas, pulmonary function, HRQOL, or six-minute walk test parameters. In addition, no safety concerns were identified for HFNC.Conclusions HFNC may be a reasonable therapeutic choice in stable hypercapnic COPD patients with a history of exacerbations.Trial registration number: UMIN000028581, NCT03282019 (http://www.umin/ac.jp, https://clinicaltrials.gov/)Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.docx and declare. Horie T reports lecture fee from AstraZeneca, Boehringer Ingelheim, Environmental Restoration and Conservation Agency, Kyorin, Novartis Pharma, and Teijin healthcare. Fukui M reports lecture fee from Teijin Pharma. Sato S reports funding from Nippon Boehringer Ingelheim. Tsuda T reports honoraria from Astrazenea, Nippon Boeringer Ingelheim, and Kyorin. Inoue H reports research/educational grants from Boehringer Ingelheim, GlaxoSmithKline, Kyorin, Novartis, and Teijin-Pharma and lectures/advisory fee from Astellas, AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Kyorin, and Novartis. Tomii K reports lecture fee from Teijin Pharma, Fisher & Paykel, Boehringer Ingelheim, AstraZeneca, and GlaxoSmithKline. No other authors have conflicts of interest to report.Clinical TrialUMIN000028581, NCT03282019Funding StatementThe study was sponsored by the Foundation for Biomedical Research and Innovation at Kobe, with funding from Teijin Pharma Limited under the study contract. The funding source of this study participated in writing the study protocol but had no role in data collection, data management, data analysis, or data interpretation. Kikuchi T, a medical statistician, and Nakagawa Y, a programmer, both of whom analyzed study data, are employees of the Foundation for Biomedical Research and Innovation at Kobe. However, the funding source did not review the analyses nor the current manuscript, and all the work was independent from the funder. English language editing service was provided by Editage (www.editage.jp).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Kobe University Clinical Research Ethical Committee (C180079)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request.